Key Insights On Assessing The Risk Factors For PAD
- Volume 21 - Issue 5 - May 2008
- 5895 reads
- 0 comments
1. Norman PE, Eikleboom JW, Hankey GJ. Peripheral arterial disease: prognostic significance and prevention of atherothrombotic complications. Med J Aust 181:150-154, 2004.
2. Price JF, Mowbray PI, Lee AJ, et al. Relationship between smoking and cardiovascular risk factors in the development of peripheral arterial disease and coronary artery disease. Edinburgh Artery Study. Eur Heart J 20:344-353, 1999.
3. Lassila R, Lepantalo M. Cigarette smoking and the outcome after lower limb arterial surgery. Acta Chir Scand 154:633-650, 1988.
4. Jonason T, Bergstrom R. Cessation of smoking in patients with intermittent claudication: effects on the risk of peripheral vascular complications, myocardial infarction and mortality. Acta Med Scand 221:253-260, 1987.
5. Fowkes FG, Houseley E, Cawood EHH, et al. Edinburgh Artery Study: prevalence of asymptomatic and symptomatic peripheral arterial disease in the general population. Int J Epidemio 20(2):384-392, 1991.
6. Jude EB, Oyibo SO, Chalmers N, Boulton AJ. Peripheral arterial disease in diabetic and nondiabetic patients: a comparison of severity and outcome. Diabetes Care 24:1433-1437, 2001.
7. Selvin E, Marinopoulos S, Berkenblit G, et al. Meta-analysis glycosylated hemoglobin and cardiovascular disease in diabetes mellitus. Ann Intern Med 141:421-431, 2004.
8. Peripheral arterial disease in people with diabetes. American Diabetes Association consensus statement. Diabetes Care 26(12):3333-3341, 2003.
9. UK Prospective Diabetes Study Group. Intensive blood glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 352:837-853, 1998.
10. The Diabetes Control and Complications Trial Research Group. The effects of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med 329:986-988, 1993.
11. Stokes J, Kannel WB, Wolf PA, Cupples LA, D’Agostino RB, Silbershatz H, et al. The relative importance of certain risk factors for various manifestations of cardiovascular diseases among men and women from 35 to 64 years old: 30 years of follow-up in the Framingham Study. Circulation 75:65-73, 1987.
12. Murabito JM, D’Agostino RB, Silbershatz H, et al. Intermittent claudication: a risk profile from the Framingham Heart Study. Circulation 96:44-49, 1997.
13. Grundy SM, Cleeman JI, Bairey Merz CN, et al. Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III Guidelines. J Am Coll Cardiol 44:720-732, 2004.
14. Ridker PM, Cushman M, Stampfer MJ, et al. Plasma concentration of C-reactive protein and risk of developing peripheral vascular disease. Circulation 97:425-428, 1998.
15. Lonn E, Yusuf S, Arnold MJ, et al. Homocysteine lowering with folic acid and B vitamins in vascular disease. N Engl J Med 354(15):1567-77, 2006.
16. Norgren L, Hiatt WR, Dormandy JA, Nehler MR, Harris KA. Inter-society consensus for the management of peripheral arterial disease (TASCII). J Vasc Surg 45:S5A-S67A, 2007.
17. National Heart, Lung and Blood Institute Web site: www.nhlbi.nih.gov/health/prof/heart/other/accord/